Runs an online platform connecting doctors with drug information, clinical trials and medical marketing.
Runs an online platform connecting doctors with drug information, clinical trials and medical marketing.
Pharmaceutical companies pay to reach its members through online advertising, surveys and clinical-trial recruiting, so revenue follows drug makers' marketing budgets rather than anything doctors pay. Overseas arms add physician networks outside Japan. Sony Group helped start the business and remains a major shareholder.
In one line: A Sony-backed medical version of a professional network like LinkedIn for doctors.
Moat: narrow (network effects, installed base). Large registered physician network creates a two-sided platform hard for new entrants to replicate.
Headquarters: Tokyo, Japan · Founded: 2000 · Employees: 17,010
Size M3 Inc (2413.T) is a Japan Health Care company (Internet Software/Services) with a market value of $7.40B, the 179th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,732 on 18 Nov 2026.
Performance Over six months the shares gained 27.9%, against +8.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 9.5% over the last twelve months (peer median +9.0%); the operating margin is 19.0% (peer median 13.4%).
Valuation It trades at 22.6× forward earnings against a peer median of 16.2× (5th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.2 points above its cost of capital (5.5% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥362B | ¥351B | ¥285B | ¥239B | ¥231B |
| Revenue growth | — | +23% | +19% | +3% | — |
| Gross profit | ¥179B | ¥161B | ¥144B | ¥133B | ¥129B |
| EBITDA | ¥87.5B | ¥87.3B | ¥73.6B | ¥74.4B | ¥77.8B |
| Net income | ¥46.4B | ¥49.1B | ¥40.5B | ¥45.3B | ¥49.0B |
| Free cash flow | n/a | ¥62.6B | ¥45.5B | ¥52.9B | ¥51.2B |
| Capital expenditure | n/a | ¥11.9B | ¥8.99B | ¥7.58B | ¥7.58B |
| Total debt | ¥36.5B | ¥60.5B | ¥51.4B | ¥31.8B | ¥10.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| M3 Inc 2413.T | $7.40B | +28% | +9% | 19% | 22.6× | 0.3% |
| Doximity DOCS | $5.47B | +59% | +6% | 27% | 21.2× | 17.0% |
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
| Veeva Systems VEEV | $44.9B | +68% | +16% | 30% | 28.7× | 23.1% |
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2413.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | +4.4% | 3rd lowest of 19 |
| 6-month return | +27.9% | +8.8% | 3rd highest of 19 |
| Distance from 52-week high | -36.0% | -10.7% | 2nd lowest of 19 |
| Revenue growth (TTM) | +9.5% | +9.0% | 9th highest of 19 |
| Operating margin | 19.0% | 13.4% | 5th highest of 19 |
| Forward P/E | 22.6× | 16.2× | 5th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 0.9% | 9th least demanding of 17 |
| Growth delivered (Del g) | +15.7% | +8.1% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -15.4 pp | -7.1 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | +7.2 pp | +2.2 pp | 4th highest of 19 |
| EV / EBITDA | 12.7× | 10.8× | 6th most expensive of 16 |
| Net debt / EBITDA | -1.3× | -0.7× | 5th least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| M3 Inc 2413.T | Japan | $7.40B | +28% | +9% | 19% | 22.6× | 0.3% | +15.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Eisai 4523.T | Japan | $9.36B | +11% | +11% | 6% | 26.6× | 10.7% | +5.0% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 12.5× | -7.2% | +3.5% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 15.9× | n/a | n/a |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 18.4× | -8.4% | +3.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |